Axsome Therapeutics Files 8-K

Ticker: AXSM · Form: 8-K · Filed: Mar 5, 2025 · CIK: 1579428

Axsome Therapeutics, INC. 8-K Filing Summary
FieldDetail
CompanyAxsome Therapeutics, INC. (AXSM)
Form Type8-K
Filed DateMar 5, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: 8-K, regulatory-filing

Related Tickers: AXSM

TL;DR

AXSM filed an 8-K on 3/5/25 - check for updates.

AI Summary

Axsome Therapeutics, Inc. filed an 8-K on March 5, 2025, to report other events and financial statements. The filing does not contain specific details about the nature of these events or financial figures within the provided text.

Why It Matters

This filing indicates that Axsome Therapeutics has made a regulatory submission to the SEC, which could contain important updates for investors.

Risk Assessment

Risk Level: low — The filing is a standard procedural document without immediate disclosed financial impact or significant operational changes.

Key Players & Entities

FAQ

What specific events are being reported in this 8-K filing?

The filing indicates 'Other Events' and 'Financial Statements and Exhibits' as items being reported, but the specific details are not provided in the text.

When was this 8-K report filed?

The report was filed on March 5, 2025.

What is the exact name of the company filing this report?

The exact name of the company is Axsome Therapeutics, Inc.

In which state was Axsome Therapeutics, Inc. incorporated?

Axsome Therapeutics, Inc. was incorporated in Delaware.

What is the principal executive office address for Axsome Therapeutics, Inc.?

The principal executive office is located at One World Trade Center, 22nd Floor, New York, New York, 10007.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on March 5, 2025 regarding Axsome Therapeutics, Inc. (AXSM).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing